Aimed Bio, a corporations developing antibody-drug conjugate (ADC) new drugs, succeeded in a "ttatta-bul" (four times the offer price) on the first day of its KOSDAQ market listing on the 4th.
As of 9:17 a.m. that day, Aimed Bio shares were trading on the KOSDAQ market at 44,000 won, up 300.00% (33,000 won) from the offer price (11,000 won).
Aimed Bio is a corporations founded in 2018 by neurosurgery professor Nam Do-hyeon of Samsung Medical Center, and it develops antibody-drug conjugate (ADC) new drugs. An antibody-drug conjugate is a therapeutic technology that attaches a drug to an antibody to deliver it precisely to target cells.
Aimed Bio drew about 15.3552 trillion won in deposits, recording a subscription competition ratio of 1,736.8 to 1 in the retail investor offering held on the 21st to 24th. In the institutional investor book building conducted earlier, the offer price was set at the top end of the desired range, 11,000 won.